Related Experiment Video

Updated: Jun 14, 2026

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

Inhibition of trans-plasma membrane electron transport: a potential anti-leukemic strategy

Cecilia Prata1, Carole Grasso, Stefano Loizzo

  • 1Department of Biochemistry G. Moruzzi, University of Bologna, Bologna, Italy. cecilia.prata@unibo.it

Leukemia Research
|March 26, 2010
PubMed

Insights

Trans-plasma membrane electron transport (tPMET) is crucial for leukemic cell survival. Targeting tPMET with new compounds shows potential as an anti-leukemic drug development strategy.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Oncology

Background:

  • Glycolytic cancer cells depend on trans-plasma membrane electron transport (tPMET) for survival.
  • The role of tPMET as a therapeutic target in cancer, particularly leukemia, requires further investigation.

Purpose of the Study:

  • To investigate the effects of novel and known compounds on leukemic cell proliferation.
  • To assess the impact of these compounds on tPMET activity and NAD(P)H fluorescence.
  • To evaluate tPMET as a potential anti-leukemic drug target.

Main Methods:

  • Utilized human myelogenous leukemic cell lines.
  • Administered new and established chemical compounds.
  • Measured cell proliferation rates.
  • Assayed tPMET activity.
  • Monitored intrinsic NAD(P)H fluorescence.

Main Results:

  • Confirmed the critical role of tPMET in the survival of leukemic cells.
  • Observed varying effects of tested compounds on proliferation and tPMET activity.
  • Demonstrated a correlation between compound effects, tPMET activity, and NAD(P)H fluorescence.

Conclusions:

  • tPMET is a vital pathway for leukemic cell survival.
  • The compounds tested influenced tPMET activity and cell proliferation.
  • tPMET inhibition presents a promising new strategy for anti-leukemic drug development.

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Related Concept Videos

Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Electron Transport Chain01:30

The Electron Transport Chain

The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q in...